Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 28 of 42
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

Alexion wraps up $1.2bn acquisition of Syntimmune

The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with